Investing.com -- Merck & Co (NYSE: MRK ) said on Monday that the U.S. Food and Drug Administration (FDA) has granted priority review to its application for expanded use of the oral cancer drug Welireg.
The expanded use would include treatment for patients aged 12 and older who suffer from advanced, unresectable or metastatic pheochromocytoma and paraganglioma, rare tumors that form in and around the adrenal glands.
This designation means the review period for the drug will be shortened. Merck (NSE: PROR ) also said that the FDA has set a target action date of May 26 for the application.
If approved by the FDA, Welireg would become the only available therapy in the U.S. for eligible patients with advanced pheochromocytoma and paraganglioma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.